Teva Pharmaceutical Industries Hits Estimates, But GAAP Results Lag Last Year's
Teva Pharmaceutical Industries (NYS: TEVA) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Teva Pharmaceutical Industries met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped significantly.
Gross margins increased, operating margins shrank, net margins dropped.
Teva Pharmaceutical Industries booked revenue of $4.90 billion. The 21 analysts polled by S&P Capital IQ looked for revenue of $4.86 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.12. The 23 earnings estimates compiled by S&P Capital IQ predicted $1.11 per share. Non-GAAP EPS of $1.12 for Q1 were 24% lower than the prior-year quarter's $1.47 per share. GAAP EPS of $0.74 for Q1 were 24% lower than the prior-year quarter's $0.97 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 52.8%, 60 basis points better than the prior-year quarter. Operating margin was 17.8%, 440 basis points worse than the prior-year quarter. Net margin was 12.9%, 390 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $4.97 billion. On the bottom line, the average EPS estimate is $1.21.
Next year's average estimate for revenue is $20.17 billion. The average EPS estimate is $5.04.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,438 members out of 2,509 rating the stock outperform, and 71 members rating it underperform. Among 526 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 519 give Teva Pharmaceutical Industries a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $45.31.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Teva Pharmaceutical Industries to My Watchlist.
The article Teva Pharmaceutical Industries Hits Estimates, But GAAP Results Lag Last Year's originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.